The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nominating molecular/immunologic drivers of central nervous system (CNS) metastases in squamous cell carcinoma of the head/neck (SCCHN).
 
Alec Kacew
No Relationships to Disclose
 
Michael Wotman
No Relationships to Disclose
 
Charles T Quinn
No Relationships to Disclose
 
Laura E MacConaill
No Relationships to Disclose
 
Ann Marie Egloff
No Relationships to Disclose
 
Stephanie M Jones
No Relationships to Disclose
 
Kathleen L. Pfaff
No Relationships to Disclose
 
Scott J. Rodig
Leadership - Immunitas
Stock and Other Ownership Interests - Immunitas
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead company; Merck
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Kartik Sehgal
Honoraria - Equinox Group; Exelixis; Medscape
Consulting or Advisory Role - Equinox Group; Exelixis; Medscape
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Consulting or Advisory Role - Achilles Therapeutics; AstraZeneca; Bayer; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Eisai; EMD Serono; Genentech; Genmab; Gilead Sciences; GlaxoSmithKline; Immunomic Therapeutics; Loxo; Merck; Mirati Therapeutics; Pfizer; Vaccinex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; ISA Pharmaceuticals; Nanobiotix
 
Marshall R. Posner
Consulting or Advisory Role - Calliditas Therapeutics; Cel-Sci; Merck
Research Funding - AstraZeneca (Inst); Hookipa Pharma (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - anti-Staphylococcal Monoclonal antibody (Inst); Uptodate editor
(OPTIONAL) Uncompensated Relationships - Vivan Therapeutics
 
Glenn J. Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Bristol-Myers Squibb; Kura Oncology
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Exicure; General Catalyst; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Prelude Therapeutics; Rain Therapeutics; Remix Therapeutics; Sanofi; SIRPant Immunotherapeutics
Research Funding - Actuate Therapeutics (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Elevar Therapeutics (Inst); Exicure (Inst); Gateway for Cancer Research; Genzyme (Inst); GlaxoSmithKline (Inst); Kartos Therapeutics (Inst); Kite/Gilead (Inst); Kite/Gilead (Inst); NantKwest, (Inst); Regeneron (Inst); Secura Bio (Inst); V Foundation
Expert Testimony - Aaronson Rappaport Feinstein & Deutsch; Ahmuty, Demers, & McManus; Wilson Elser Moskowitz Edelman & Dicker, LLP